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Psoriasis is more than a skin disorder. An ACE study.
Abstract
Introduction: Psoriasis is now known to be a systemic autoimmune disease with an associated 
increased cardiovascular risk. This seems to rely on systemic inflammation. Angiotensin-converting 
enzyme (ACE) has been associated with oxidative stress, a state characteristic of cardiovascular 
disorders and this enzyme’s activity is higher in psoriasis. Our aim is to assess cardiovascular risk in 
psoriatic patients and its association with ACE polymorphism and activity.
Methods: Our population consisted of 1155 individuals (64 psoriatic patients, 1091 controls) 
whose ACE genotype and activity were determined. The cardiovascular risk was estimated through 
lipid profiles. PASI score was used as a severity measurement.
Results: Psoriatic severity was associated with a higher cardiovascular risk estimated by lower 
HDL concentrations (r=-0.496, p=0.007) and higher triglyceride levels (r=0.421, p=0.020), as well 
as TC/HDL and LDL/HDL ratios (r=0.612, p<0.001 and r=0.437, p=0.023, respectively) which 
have been shown to have stronger predictive value for cardiovascular disorders
Conclusions: Psoriatic patients should be treated as a risk group for cardiovascular diseases 
and new markers for severity and this associated risk may be of worthy pursuit. Further studies are 
crucial to enhance our knowledge on inflammation and psoriasis.
Keywords: ACE, Psoriasis, Cardiovascular Risk, Lipid profile
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Resumo
Introdução: A psoríase é atualmente vista como uma doença sistémica autoimune com um 
risco cardiovascular associado, cuja correlação parece advir de um estado de inflamação sistémica. 
A  enzima  conversora  de  angiotensina  (ECA)  associa-se  a  stress  oxidativo,  característico  da 
patologia cardiovascular e apresenta níveis de atividade superiores na psoríase. O nosso objetivo é 
avaliar este risco e a sua associação com o polimorfismo e atividade do ECA.
Métodos: A amostra consiste em 1155 indivíduos (65 psoriáticos, 1091 saudáveis), dos quais 
se determinou o genótipo do ECA e a sua atividade. O risco cardiovascular foi estimado a partir do 
perfil lipídio e a severidade da doença pelo índice PASI.
Resultados: A severidade da psoríase associou-se a diminuição do HDL (r=-0.496, p=0.007) e 
aumento  dos  triglicerídeos  (r=0.421,  p=0.020),  bem  como  dos  índices  CT/HDL e  LDL/HDL 
(r=0.612, p<0.001 e r=0.437, p=0.023, respetivamente), os quais traduzem melhor valor preditivo 
para doenças cardiovasculares.
Conclusões:  Os  doentes  psoriáticos  devem  ser  tratados  como  um  grupo  de  risco  para 
patologia cardiovascular e deverão ser procurados novos marcadores para a severidade da doença e 
risco associado. Novos estudos são essenciais para melhorar o conhecimento nesta área.
Palavras chave: ECA, Psoríase, Risco Cardiovascular, Lípidos
O Trabalho Final exprime a opinião do autor e não da FML.
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Psoriasis is more than a skin disorder. An ACE study.
Introduction
Psoriasis affects approximately 2% of the population worldwide [1,  2],  accounting for 12 
million individuals within the USA and Europe [3], with a higher prevalence at higher latitudes and 
also more prevalent among caucasians [4].
Psoriasis  can  present  at  any  age  and  in  different  ways.  It  can  be  classified  according  to 
morphologic  appearance  including  plaque,  inverse,  erythrodermic,  pustular,  and  guttate  forms, 
sometimes with nail manifestations as well, including nail dystrophy and psoriatic lesions of the 
nail bed [2, 5]. The most common clinical variant is psoriasis vulgaris, representing 90% of all 
cases.  This  type  of  psoriasis  is  usually  manifested  as  well  circumscribed  red  or  salmon  pink 
papulosquamous plaques covered by silvery scales surrounded with normal skin. Manifestations are 
generally symmetrically distributed in the body, specially on the extensor area of the elbows and 
knees, on the scalp, and lumbosacral region [1, 6], although any or all portions of the body surface 
may be affected.
Patients  with  psoriasis  have  a  higher  prevalence  of  numerous  comorbidities,  such  as 
pulmonary, renal, hepatic, rheumatologic and cardiovascular diseases [7] with a clear majority of 
the  literature  revealing  a  correlation  between  psoriasis  and  cardiovascular  risk,  linking  it  with 
disorders  such  as  obesity,  hypertension,  dyslipidemia,  diabetes  mellitus  (DM)  and  metabolic 
syndrome. This epidemiologic association seems to be stronger as psoriasis is  more severe [8]. 
Even though there are multiple definitions of disease severity,  it  is  accepted by most that  mild 
psoriasis has less than 3% body surface area involved, moderate psoriasis between 3 and 10% and 
severe  psoriasis  more  than  10%  body  surface  area  involvement,  as  proposed  by  the  National 
Psoriasis Foundation [9]. 
Obesity, a well known cardiovascular risk factor, has been studied as a comorbidity in patients 
with psoriasis and the association has been shown to grow with the severity of psoriasis, with an 
adjusted odds ratio (OR) of 1.79 (95% CI [1.55,2.05]) for patients with severe psoriasis and 1.27 
(95% CI  [1.24,1.31])  among  the  ones  with  mild  psoriasis  [10].  Despite  there  being  a  definite 
connection between the two it is not yet established wether obesity predates or comes after the 
development of psoriasis. Just as the definition of OR itself explains, it does not establish a cause-
effect relation in either direction and it could even be that the association is due to a third property, 
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which  is  a  contributing  factor  for  both  psoriasis  and  obesity,  or  even  a  common  underlying 
pathophysiology.  In  fact  there  is  both  evidence  of  a  BMI increase  in  patients  after  they  were 
diagnosed with psoriasis [11], pointing to obesity as secondary to the disease, and strong evidence 
that  indicate  that  obesity  is  a  risk  factor  for  the  development  of  psoriasis,  with  both  hip 
circumference and waist-hip ratio associated with higher risk of psoriasis [12, 13].
This “psoriasis’ obesity” is believed to be an important connection to all other cardiovascular 
disorders and risk factors among these patients. There is even a tendency for central adiposity as 
shown in a study which illustrated that children and adolescents with psoriasis are more prone to 
obesity and that this obesity is more likely abdominal [14], and waist circumference, waist-hip ratio 
or any other central adiposity measures are presumed to be more relevant to cardiovascular risk than 
an increased BMI [15, 16]. In a 24 week study there was much more significant results in reducing 
disease severity when cyclosporine therapy was combined with a low-calorie diet as opposed to 
cyclosporine alone [17], suggesting that obesity may also affect treatment efficacy.
Pathophysiologically, psoriasis seems to share many cytokines with obesity, such as TNF-α 
and IL-6. There is a shown rise of both serum TNF-α levels and TNF-α receptors as BMI and waist 
circumference increase [18] and there is also higher levels of c-reactive protein (CRP) in psoriatic 
populations  as  well  as  a  positive  association between its  levels  and BMI [19],  being not  only 
increased in active stages of disease but also during remission compared to controls [20]. 
In  regards  to  hypertension,  there  have  been  studies  that  suggest  a  correlation  between 
psoriasis and hypertension as well as the difficulty to control it [21]. This correlation seems to be 
severity dependent [22]. 
Dyslipidemia  has  also  been  associated  with  psoriasis.  Triglyceride,  total-cholesterol,  and 
LDL-cholesterol levels were found to be higher in psoriatic patients [23, 24], and these changes 
were seen at the onset of the disease [25], leading to the possibility that dyslipidemia may precede 
psoriasis. It is however unclear whether this lipid profile changes are due to the increased incidence 
of obesity in psoriatic populations and its influence in lipid metabolism or actually independently 
associated with psoriasis.  Adipocytes release a variety of pro inflammatory molecules including 
some  cytokines  such  as  TNF-α  and  IL-6.  These  molecules  are  shown  to  not  only  increase 
cardiovascular risk [26] but also to affect free fatty acids, cholesterol and lipid levels [27]. There 
have been a few studies that found an atherogenic profile with decreased total HDL levels and 
higher levels of small LDL and HDL particles in psoriatic patients, measured by nuclear magnetic 
resonance spectroscopy, and these were shown to be associated with increased aortic inflammation, 
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which  suggests  that  HDL  particle  characteristics  may  be  an  important  participant  in  the 
cardiovascular risk seen in psoriasis [28, 29]. The same study found a lower HDL efflux capacity in 
psoriatic patients, which is associated with non calcified coronary atherosclerosis, non related to the 
HDL levels  [30].  This  decrease  in  cholesterol  efflux  may  be  explained  by  another  study  that 
describes psoriatic HDL as having diminished phospholipid and cholesterol  components,  which 
results in the reduction of its capacity to promote cholesterol efflux from macrophages. This efflux 
capability was negatively correlated with psoriasis area and disease severity [31].
Another important comorbidity is the metabolic syndrome, that in a way correlates most of 
the comorbidities discussed above. It is directly linked to intra-abdominal obesity, and is perceived 
as a setting of chronic systemic inflammation that meets at least three of the following: abdominal 
obesity, impaired glucose regulation, hypertriglyceridemia, reduced HDL and hypertension [32]. 
The association has been proved in many studies, with abdominal obesity as the most common 
criteria met by the psoriatic group, followed by hypertriglyceridemia and decreased levels of HDL 
[33]. 
This abdominal obesity must be recognized almost as an endocrine organ that is in fact able to 
release  many bioactive  peptides  (adipokines)  such as  TNF-α,  IL-6,  leptin  and adiponectin  that 
coordinate inflammation, glucose and lipid metabolism and endothelium function [34]. 
Adipocytes may also interact directly with macrophages that are increased in the dermis and 
which,  by releasing TNF-α,  will  influence gene transcription in adipose tissue,  augmenting the 
levels  of  leptin  in  decrement  of  adiponectin  levels  which  is  an  important  anti-inflammatory 
molecule that also functions in regulating insulin sensitivity, and block insulin signaling, becoming 
a major contribute for insulin resistance [35]. This insulin resistance was shown to be present in the 
dermal endothelium of both psoriatic plaques and “normal” skin in patients with psoriasis and it 
promotes  endothelial  expression  of  adhesion  molecules  and inflammation  by shifting  anti-/pro-
atherogenic insulin-dependent pathways towards the latter [36]. Furthermore, it has also a role in 
regulating keratinocytes, since some of the cytokines that cause this shift and the consequent insulin 
resistance,  namely  IL-1β,  are  also  responsible  for  disrupting  insulin-dependent  keratinocyte 
differentiation and thus boosting keratinocyte proliferation [37], one of the most discussed features 
of psoriatic skin.
TNF-α, besides inducing insulin resistance, increasing production of adhesion molecules by 
endothelial cells and having a positive correlation with BMI as discussed above, also augments free 
fatty acids which further induce insulin resistance, all of which are crucial steps for endothelial 
damage and  atherogenesis  [38].  Additionally,  IL-6  too  induces  insulin  resistance  and  increases 
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adhesion molecules production. It also stimulates the liver to release fibrinogen and CRP, all of 
which further encourage atherosclerosis [39]. 
Adiponectin seems to work against these actions, augmenting insulin sensitivity, decreasing 
TNF-α production and monocyte cell adhesion and reducing transformation of macrophages into 
foam cells [40], which is a feature of atherosclerosis [41]. It is positively correlated to weight loss 
and high levels of adiponectin have been shown to confer lower risk for myocardial infarction (MI) 
in men [42]. This adipokine’s plasma levels seem to be negatively correlated with BMI,  as opposed 
to leptin, which increases with both BMI and waist circumference. Adiponectin decreases more in 
relation to visceral adiposity than to subcutaneous adipose tissue [43]. Adiponectin was also found 
to be decreased in hypertension and ischemic heart disease [44, 45].
Leptin, on the other hand, seems to have opposite effects. In a study that compared different 
ethnicities, individuals at high risk for cardiovascular diseases and metabolic syndrome had higher 
levels of plasma leptin [46], which goes hand to hand with a study that found increased leptin to 
affect carotid intima-media thickness (CIMT) [47]. Leptin was also shown to be higher in patients 
with psoriasis, working as a severity marker [48].
Finally,  another comorbidity that has been associated with psoriasis is  type II  diabetes.  A 
recent study confirmed that patients with psoriasis had higher rates of DM and this higher risk was 
once again severity dependent [49], as it was shown before [10, 50]. This association could be due 
to the many insulin resistance mechanisms explained before, mainly driven by TNF-α, however 
psoriasis seems to be associated with a diabetes susceptibility locus which might suggest a stronger 
correlation from the base [51], and the association between psoriasis and DM is shown to still be 
present when adjusted for BMI [52].
Psoriasis has been, as discussed above, linked to various comorbidities and it’s also associated 
with an increased mortality, specially in cases of severe psoriasis [53, 54].  This increased risk of 
death has been said to have numerous etiologies including infection, kidney disease and dementia 
however to be mainly due to cardiovascular problems [55] and markedly seen in young patients 
with severe psoriasis in which the risk of MI is significantly higher. [56]
It is also important to note the association between psoriasis and both CIMT and coronary 
artery calcification (CAC), which seem to be good parameters when in search for a cardiovascular 
risk  measurement  [57-60].  A study  in  2016  showed a  significant  adjusted  association  between 
CIMT and PASI (psoriasis area and severity index), which is a score of affected body area and 
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severity in psoriasis [61]. The mean CAC was also shown to be increased in other studies when 
comparing psoriatic patients to controls [62].
One  of  the  mechanisms  proposed  to  link  psoriasis  and  cardiovascular  disorders  is 
inflammation and despite the fact that, for a long time, psoriasis was seen as a skin disease, there 
has been growing and now significant evidence of it being a systemic disorder with an underlying 
systemic  inflammatory  process.  We  should  therefore  perceive  psoriases  as  a  common,  chronic 
systemic disease most frequently manifested by skin lesions [5]. 
Inflammation has been associated with cardiovascular risk, on one hand because it plays a 
central  role in atherosclerosis,  which is another mechanism that has been conjectured as a link 
between psoriasis  and cardiovascular  diseases [50],  and on the other  hand because it  has been 
suggested  that  chronic  inflammation  itself  may  lead  to  an  exacerbation  of  cardiovascular 
complications, with a possibility that this effect might actually work through vascular damage as 
well. A study using murine models with psoriasiform dermatitis without any comorbidities showed 
aortic root inflammation in 33% of the affected group compared with 0% in controls (p=0.04) and 
concluded that skin-specific inflammation promotes both vascular inflammation and an increase in 
thrombotic rates and that treatment against this skin inflammation attenuates these pathways [63]. In 
fact, systemic treatments targeting psoriatic underlying inflammation have been studied and shown 
to  improve  both  psoriasis  and  the  cardiovascular  disorders.  Methotrexate  was  proven  to 
significantly reduce vascular disease risk, specially when given in lower doses [64], which could be 
explained  by  the  fact  that  in  lower  doses  methotrexate’s  anti-inflammatory  properties  might 
outweigh its influence in homocysteine levels, that are shown to augment cardiovascular risk [65, 
66], supported by the same study in which the association of folic acid to the high dose treatment 
improved the outcomes as well [64]. There was also a study in which etanercept had a lowering 
influence on CRP levels  [19]  and this  inflammatory protein has been shown to add prognostic 
information in the prediction of future cardiovascular events beyond that given by all lipid measures 
[67]. In 2011, another study demonstrated that an anti-psoriatic treatment improved endothelial cell 
disfunction [68].
Atherosclerosis has an undeniable bond with psoriasis as it is significantly more prevalent in 
psoriatic patients with an adjusted OR (for gender, race, BMI, smoking status, hypertension, HDL 
and CRP) of 2.67 (95% CI [1.20,5.92]), having an even stronger association when adjusted for age, 
since  there  is  an  excess  of  atherosclerosis  in  younger  psoriatic  groups  [69],  and  because  both 
plaques have similar inflammatory cell infiltrates in their content [70]. Psoriasis is a Th1, Th17 and 
Th22  inflammatory  disease,  with  expansion  and  activation  of  these  T  cells  subsets,  antigen 
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presenting  cells  and  the  subsequent  cytokines  [71,  72]  and  these  Th1  and  Th17  cascades  are 
common to atherosclerosis [70].  The activation of these pathways and its cytokines such as IL 17 
and IL 6, increased in psoriasis, also help further progression of atherosclerotic plaques and are 
accordingly found increased in cases of unstable coronary artery disease [73, 74]. Monocytes, that 
are known to promote arterial smooth muscle proliferation and transformation of macrophages into 
foam cells within the vessel wall [75, 76] have an increased aggregation that is characteristic of 
psoriatic inflammation [77]. Furthermore, raised levels of monocyte chemoattractant protein-1 and 
macrophage-derived chemokine are associated with cardiovascular risk, specifically atherosclerotic 
plaque instability and rupture [78] and are found increased in skin lesions and serum of psoriatic 
patients [79].
Insulin resistance is yet another mechanism suggested to contribute to cardiovascular diseases 
in psoriasis, however it is thought to be induced by chronic inflammation [80] and it seems to play a 
massive role in atherosclerosis [81, 82], so it might just be a part of the same extensive mechanism 
where changes like insulin resistance, atherosclerosis and dysregulation of adipose tissue, that lead 
to the many comorbidities discussed above, are driven by cytokines and other pro-inflammatory 
mechanisms, which appear to be over regulated in psoriasis. These changes seem to further amplify 
inflammation, creating a sort of vicious cycle between psoriasis and cardiovascular diseases [83].
A relevant  and  currently  discussed  part  of  psoriasis  and  its  development  is  the  genetic 
background. Besides the commonly discussed genes involved in psoriasis (PSORS1-13, D2S134) 
[84] there seem to be different genetic factors that contribute to disease susceptibility [85]. One 
example  of  these  might  be  the  angiotensin-converting  enzyme  (ACE)  insertion/deletion  (I/D) 
polymorphism. 
ACE is a carboxypeptidase that cleaves angiotensin I into the vasoactive angiotensin II in the 
endothelium surface and that also degrades bradykinin, a strong vasodilator, providing a double 
vasoconstrictive effect. Angiotensin II increases formation of reactive oxygen species, stimulates 
the synthesis of cytokines including IL6 and IL8 [86, 87], which are present in the pathogenesis of 
both psoriasis and cardiovascular diseases as discussed previously, and promotes insulin resistance 
[88], which suggests that higher levels of ACE would be in concordance with the pathophysiology 
of  psoriasis.  On  the  other  hand,  bradykinin  has  a  pro-inflammatory  effect  as  well,  enhancing 
synthesis of IL6 and IL8 [89], indicating that lower levels of ACE or even ACE inhibition could 
favor the inflammatory state seen in psoriasis. ACE-inhibitors have in fact been associated with 
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exacerbations and even appearance of  psoriasis  [90,  91].  Favoring the first,  higher  ACE levels 
suggest a state of oxidative stress, characteristic of cardiovascular disorders [92].
The ACE gene is located on chromosome 17q23 and has 26 exons and 25 introns. On intron 
16 a polymorphism was detected, defined by an insertion or a deletion of a 287 bp non coding Alu 
repeat sequence [93] that  has been shown to affect  ACE levels and function [94].  Serum ACE 
concentrations were found higher in DD homozygotes, with the I/D polymorphism accounting for 
47% of the variability in these concentrations [95].
Multiple studies showed an increment in serum ACE activity in patients with psoriasis when 
compared to healthy controls [96], which decreased to identical levels as those seen in controls after 
treatment  for  psoriasis.  Various  psoriatic  treatments  were  studied  and  there  was  no  significant 
difference on how ACE levels dropped in each case [97], suggesting that ACE could be an useful 
measurement for therapeutic efficacy.
A study using murine models showed that inflammation reduced the ACE2/ACE ratio, with a 
clear decrease in ACE-2 levels and a trend to increase ACE gene expression [98], pointing to the 
possibility that higher levels of ACE in patients with psoriasis could be due to the inflammatory 
state that this disease involves [99] and the consequent shift in the ACE2/ACE balance, which is 
also favored by the fact that any type of treatment decreased ACE levels to levels identical to those 
seen  in  healthy  controls.  ACE-2  was  discovered  to  balance  the  pro-inflammatory  and 
vasoconstrictive effects of the ACE/angiotensin II/AT1 axis, through the ACE2/angiotensin-(1-7)/
Mas counter-regulatory axis [100].
Because of  the seen alterations in  ACE levels  in  psoriatic  patients  and also the common 
pathways that seem to exist between the two, its polymorphism has been studied in this population. 
Studies  are  conflicting  in  the  matter,  showing  either  no  association  between  the  ACE  I/D 
polymorphism and the risk of psoriasis [101], or contradictory results regarding which genotype is 
associated with a risk for psoriasis:
• within the Asian ethnicity a few studies show that the ACE II genotype and I allele might 
confer susceptibility to psoriasis [102, 103];
• studying a Turkish population, the distribution of the ACE I/D polymorphism didn’t have 
significant differences in psoriatic patients when compared to controls, nonetheless the I allele 
was found to be significantly associated with familial psoriasis. Furthermore, onset was earlier in 
patients with familial psoriasis carrying the I allele [104];
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• in an Austrian study,  the analysis  of  all  psoriatic patients showed a significantly higher 
prevalence of the II genotype than in controls, with a stronger association when restricting the 
study to patients with early-onset psoriasis [105];
• a greek study found, however, the D allele and ID genotype to be more common in patients 
with early onset psoriasis [106].
In terms of cardiovascular risk, besides the well-known factors such as smoking, hypertension 
and DM, there are individual inherited factors that play a role in the development of cardiovascular 
diseases, which is supported by the fact that only a fraction of patients with said risk factors have in 
fact a cardiovascular event. The ACE I/D polymorphism has been studied and proposed to be one of 
these inherited factors. One study with a 518 patient population showed a clear association between 
the D allele and a higher rate of major cardiovascular events with a hazard ratio of 1.64 (95% CI 
[1.27,1.98] P < 0.001) [107]. The DD genotype was also found to be associated with an increased 
risk  of  left  ventricular  hypertrophy [108]  and both  the  DD and the  ID genotypes  have shown 
significant associations with the development of coronary artery disease [109].
This study’s purpose is to correlate the cardiovascular risk in psoriasis with the ACE I/D 
polymorphism and more importantly this enzyme’s activity levels, whose association to psoriasis 
despite having conflicting results may be one of the genetic and molecular factors that significantly 
influences cardiovascular risk within this group of patients. In order to assess the cardiovascular 
risk, as many have done before, the lipid profile was used with its many parameters that have been 
shown  to  have  a  good  predictive  value  regarding  cardiovascular  disorders  [110].  In  fact, 
abnormalities in lipoprotein metabolism are one of the key factors in atherogenesis (the basis for a 
great number of cardiovascular disorders), shown to represent around 50% of the modifiable risk of 
developing cardiovascular disease [111].
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Methods
This study utilizes data from 64 patients with psoriasis, whose blood samples were analyzed 
by the genetics lab team from Faculdade de Medicina da Universidade de Lisboa and were granted 
for the purpose of this study by Ângela Gil, Masters in Human Biology and Genetics. These blood 
samples belong to patients with psoriasis from the Dermatology department in Hospital de Santa 
Maria - Centro Hospitalar Lisboa Norte, and were provided by Paulo Filipe, PhD MD and Joana 
Antunes, MD.
The control group includes data from 1091 individuals obtained in Clínica de Endocrinologia, 
Diabetes e Metabolismo de Lisboa and granted by Mário Rui Mascarenhas, PhD MD and Joana 
Ferreira, PhD student MD.
With the blood samples, DNA extraction, quantification and amplification were performed 
using a modified salting out method, the NanoDrop spectrophotometer, PCR with specific primers 
for the ACE polymorphism and the GeneAmp PCR System 2700 thermal cycler. Afterwards, a gel 
electrophoresis allowed a determination of the patients’ genotype based on how the DNA fragments 
moved  through  the  matrix  of  agarose  reflecting  their  size  (Restriction  Fragment  Length 
Polymorphism technique) and therefore wether that sample had two larger phenotype fragments as 
in  the  II  genotype,  two  smaller  ones  (DD genotype)  or  one  of  each  in  the  ID  genotype  (see 
attachment 1).
The  enzyme  activity  was  also  determined  by  recording  the  decrease  in  absorbance  of 
furylacryloyl-phenylalanyl-glycyl-glycine (FAPGG) at 346 nm for 15 minutes at 37ºC, since ACE 
also mediates this substrate’s cleavage. 
In addition to the ACE genotype, the data collected from both the psoriatic and the control 
group included age,  gender,  BMI (only available for  the control  group),  total  cholesterol  (TC), 
HDL, LDL and triglycerides with missing information in a few individuals. Further calculations 
were performed to obtain the nonHDL cholesterol levels (TC - HDL) and the LDL/HDL ratio. 50 of 
the 64 psoriatic patients also had their PASI score calculated.
The statistic analysis was performed with the IBM SPSS Statistics 24.
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Results and discussion
This  study’s  populations  display  a  clear  difference  between  the  gender  frequencies,  with 
76.7% males to 23.3% females in the control group and 29.7% males to 70.3% females in the 
psoriatic group. In order to surpass this discrepancy all tests comparing the two populations were 
either performed separately for female and male subjects or adjusted for gender. In terms of age, it 
is shown in table 1 that both groups are similar with a calculated non significant correlation using a 
t-test and therefore no major adjustment is required.
Table 2 shows the ACE genotype frequencies in the psoriatic and control groups. The control 
group is in the Hardy-Weinberg equilibrium as seen by the chi-square test (χ2=0.718, p=0.698). It 
was also checked for the psoriatic group which was likewise found to be distributed according to 
the equilibrium (χ2=0.204, p=0.903).
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Psoriatic patients Controls
Age female 53.18±13.03
(n=17)
54.71±13.95
(n=837)
male 51.73±13.06
(n=40)
55.61±12.75
(n=254)
total 52.16±12.95
(n=57)
54.92±13.68
(n=1091)
Table 1: analysis of the characteristic age with mean±standard deviation and number of cases
Psoriatic patients Controls
ACE I/D 
polymorphism
II 11.5%
(n=7)
13.3%
(n=59)
ID 41.0%
(n=25)
43.8%
(n=194)
DD 47.5%
(n=29)
42.9%
(n=190)
p=0.777
ACE allele I 32.0%
(n=39)
35.2%
(n=312)
D 68.0%
(n=83)
64.8%
(n=574)
p=0.480
Table 2: frequencies of the ACE polymorphism and alleles and respective number of cases; p-values 
from chi-square test; significance level defined as p≤0.05
In terms of genotype frequencies, the DD genotype appears to be more frequent in psoriatic 
patients. However, once a chi-square test is executed, no correlation is shown to be statistically 
significant. The same for the analysis of both alleles (also in table 2), with the D allele in higher 
frequency in  the  psoriatic  group but,  once  again,  the  chi-square  test  not  showing a  significant 
correlation between them and the disease. This result, despite being negative, supports some of the 
data discussed above where a lack of consistency in results is predominant [101-106]. There is also 
no significant difference between both genders.
Once analyzing ACE activity instead of the genotype, this enzyme’s activity is found to be 
significantly higher in female psoriatic patients, with a strong tendency to also be increased in male 
psoriatic  patients  when  compared  to  controls  (table  3).  When  adjusting  for  gender,  the  entire 
psoriatic population was still found to have significantly higher ACE activity levels than controls.
When  analyzed  if  the  ACE activity  was  influenced  by  its  genotype  (table  4)  using  both 
psoriatic patients and controls, a higher activity level corresponded to the DD genotype and an 
intermediate level was found in the heterozygote population. As mentioned before, this result is in 
agreement with previous studies [94, 95], despite being also known that the genotype only accounts 
for about half of the variability of the enzyme’s levels.
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Psoriatic patients Controls
ACE activity female 17.38±7.67
(n=6)
11.62±6.59
(n=220)
p=0.037
male 19.83±14.66
(n=14)
12.76±6.96
(n=56)
p=0.063
total 19.09±12.80
(n=20)
11.85±6.67
(n=276)
p=0.015
p=0.049*
Table 3: means for ACE activity displaying the standard deviation and number of cases for each subgroup; p-values 
calculated with t-test or Mann Whitney test according to the distribution of the samples; significance level defined at 
p≤0.05; *p-value adjusted for gender with linear regression
ACE activity
ACE I/D 
polymorphism
II 7.75±3.31
(n=24)
ID 11.27±5.62
(n=101)
DD 14.57±8.70
(n=93)
p<0.0001
Table 4: ACE activity for each ACE genotype with mean±standard 
deviation and number of cases; p-value calculated with a kruskal-wallis 
test; significance level defined at p≤0.05
Once  analyzing  this  correlation  in  both  groups  separately,  the  association  appears  to  be 
stronger in the control group, which might support the idea that the increase in ACE activity in 
psoriatic  patients  compared  to  healthy  subjects  could  be  due  to  other  mechanisms  and  not 
dependent on the ACE genotype which in fact seems to have similar frequencies in both groups. 
When using a two-way ANOVA test to check the influence of psoriasis adjusted for the genotype it 
is still significant (p=0.004). In conclusion, genetics seem to play a smaller role in the variability of 
ACE activity in individuals with psoriasis versus healthy subjects and this might be due to some 
kind of stimuli that maintains ACE levels higher in psoriatic patients regardless of their genotype. 
A study in 2008 demonstrated using murine models that the skin, besides playing a known 
important role in the adaptation to environmental changes (with its vascular plasticity), is in fact a 
critical  mediator  of  systemic  responses  to  environmental  oxygen  [112].  This  study  showed  a 
response to hypoxia through the epidermal transcription factor HIF-1α which induces nitric oxide 
release to increase erythropoietin expression. Transposing this to psoriatic patients, it is possible 
that  their  skin suffers from hypoxia due to the cellular  hyperproliferation (characteristic in this 
disease) which would then lead to the mentioned release of NO and could explain the differences 
seen in ACE activity when comparing to the control group. Higher ACE levels suggest an oxidative 
stress state which is present in many cardiovascular disorders and is in fact one of the precipitating 
factors for atherogenesis [92, 113].
Considering  the  lipid  profile  as  the  cardiovascular  risk  measurement  for  this  study  and 
pursuing the analysis of the possible association between ACE and cardiovascular disorders, only a 
weak correlation could be found between ACE activity and LDL/HLD ratio (r=0.133, p=0.05). No 
other correlation between this enzyme’s activity and different cholesterol measures was found to be 
significant when analyzing all subjects. 
The  means  of  ACE  activity  are  different  when  dividing  the  subjects  into  two  groups 
considering the lipid concentration found to be the limit for pathologic levels. For example, looking 
at the subjects with a considered normal total cholesterol, a lower mean of ACE activity is found 
when comparing them to the subjects with a TC ≥ 190 mg/dl, and the same goes for the other lipid 
parameters. However, these differences in means are nonsignificant. It is felt that a larger psoriatic 
sample with their ACE activities measured would be of importance to assess the true influence of 
this enzyme in the cardiovascular risk seen in these patients.
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In this study, more parameters within the lipid profile were measured, such as the mentioned 
LDL/HDL ratio, TC/HDL ratio and non-HDL cholesterol levels. It has been established that LDL 
cholesterol  levels  are  not  informative  enough  regarding  the  lipoprotein  metabolism  and  these 
“atherogenic indices” have been defined in order to optimize this predictive capacity. LDL becomes 
even less reliable, in terms of its calculation, when triglyceride concentration exceeds 300mg/dl 
[110],  which  is  true  for  a  part  of  the  individuals  suffering  from dyslipidemia.  LDL may  also 
underestimate  the  magnitude  of  the  lipoprotein  abnormality  in  these  patients  since  it  does  not 
account for VLDL or IDL, which is where the non-HDL outweighs LDL predictive value [110].
Total cholesterol on its own is also a flawed indicator since it displays no difference between 
an increase in HDL cholesterol or an increase in LDL. Total cholesterol, HDL, and TC/HDL ratio 
were compared between healthy subjects and myocardial  infarction survivors and the ratio was 
found to have less overlap of populations [114]. 
When it comes to HDL, reduced concentration levels mean reduced anti-atherosclerotic trait 
and are associated with various risk factors. It probably implicates independent risk [115] and is 
critical to assess, giving the ratios a good predictive value [110].
In conclusion, the weak correlation between ACE activity and LDL/HDL ratio may be more 
meaningful than is apparent, however the lack of other correlation with HDL, non-HDL and TC/
HDL ratio makes it less likely that a clear association exists between ACE activity and a worse lipid 
profile.
The  fact  that  the  control  group  consists  of  a  population  of  patients  followed  in  an 
endocrinology  clinic  raises  the  question  as  to  wether  it  is  a  good  sample  of  the  non-psoriatic 
population,  since in terms of obesity,  DM and hypertension this  population may have a higher 
prevalence than the general population. The statistical analysis should therefore be adjusted for such 
pathologies.
Despite  the lack of  information regarding BMI in the psoriatic  group,  it  is  clear  that  the 
control group has a very large proportion of individuals with increased BMI. Once excluded the 
population with a BMI≥30kg/m2, there is a tendency for an increase in nonHDL cholesterol with a 
higher ACE activity (r=0.146, p=0.082). In the same circumstances, the correlation between ACE 
activity and LDL/HDL ratio becomes slightly stronger (r=0.209, p=0.016). One would expect such 
modification considering the fact that obesity is an inflammatory disease as well as psoriasis and 
could therefore have a stronger influence on the cardiovascular risk masking the effect of psoriasis 
or in this case ACE levels. Even these levels may be influenced by the coexistence of obesity. In 
fact, in 2002, a study showed a decrease in serum ACE related to weight loss in obese subjects 
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[116]. Although these results are not significant since this variable was only accounted for in the 
control group, they are mentioned as an indication of the possible positive changes in this study’s 
results if this exclusion criterion could be met for all subjects involved. 
When trying to assess the differences in cardiovascular risk between psoriatic patients and 
controls, even though lower levels of HDL, higher TC/HDL and LDL/HDL ratios appear to be 
associated with psoriasis, once adjusted for gender and age these associations become statistically 
nonsignificant (table 5).  
If  the  obese population (BMI≥30kg/m2)  is  excluded the results  are  more promising.  It  is 
important to remember that this exclusion criterion could not be met in the psoriatic group because 
of  lacking  information.  However,  since  obesity  has  so  many  interactions  with  what  is  being 
analyzed, it is felt to be of interest to show the massive change in outcomes.
A significant association was found between lower levels of HDL and psoriasis as well as 
with higher levels of ACE activity (table 6), after adjustment for age and gender. There is also a 
strong tendency for an increase in TC/HDL ratio and triglyceride levels in psoriasis, which comes in 
agreement with many of the basis of this study as well as previous studies [117].
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Total 
cholesterol
HDL 
cholesterol
TC/HDL 
ratio
non-HDL 
cholesterol
LDL 
cholesterol
LDL/HDL 
ratio
Triglycerides
Psoriatic 
patients
female 207.73±65.50
(n=11)
60.18±17.55
(n=11)
3.45±0.43
(n=11)
147.55±51.07
(n=11)
132.90±50.90
(n=10)
2.13±0.44
(n=10)
119.82±113.84
(n=11)
male 185.17±30.95
(n=24)
44.13±9.35
(n=23)
4.37±1.08
(n=23)
141.70±31.04
(n=23)
112.09±29.10
(n=22)
2.65±0.87
(n=22)
143.00±60.54
(n=25)
total 192.26±44.98
(n=35)
49.32±14.48
(n=34)
4.08±1.01
(n=34)
143.59±37.95
(n=34)
118.59±37.71
(n=32)
2.49±0.79
(n=32)
135.92±79.58
(n=36)
Controls female 201.71±37.63
(n=653)
61.10±13.88
(n=647)
3.45±0.94
(n=647)
140.86±36.96
(n=647)
119.61±34.03
(n=615)
2.06±0.77
(n=615)
106.54±52.65
(n=642)
male 193.46±38.84
(n=221)
48.63±12.28
(n=216)
4.18±1.17
(n=216)
145.04±38.53
(n=216)
119.57±33.90
(n=204)
2.60±0.92
(n=202)
137.50±86.41
(n=218)
total 199.62±38.09
(n=874)
57.98±14.53
(n=863)
3.63±1.06
(n=863)
141.91±37.38
(n=863)
119.60±33.98
(n=819)
2.19±0.84
(n=817)
114.39±64.32
(n=860)
p=0.139
p=0.437*
p=0.042
p=0.153*
p=0.008
p=0.383*
p=0.801
p=0.926*
p=0.882
p=0.797*
p=0.047
p=0.566*
p=0.118
p=0.733*
Table 5: means for the different parameters of the lipid profile with standard deviation and number of cases for each subgroup; p-values calculated with t-test or Mann Whitney 
test according to the distribution of the samples; significance level defined at p≤0.05; *p-values adjusted for gender and age using linear regression
This result reinforces the idea that obesity does have an influence when it comes to assessing 
the  ACE and  psoriatic  effect  on  lipid  profile  and  therefore  BMI  should  be  calculated  in  both 
populations (controls  and psoriatic)  for  a  future study.  It  would also be relevant  to inquire the 
subjects of both groups about their usual medication and exclude or adjust these findings to the 
intake of statins, other cholesterol lowering agents or any cardiovascular risk altering medication. 
Diabetes and hypertension are also comorbidities that influence cardiovascular risk and might be 
associated  with  psoriasis  as  discussed  above  and  therefore  should  be  considered  in  both  the 
psoriatic and control groups and used to adjust statistical results. The clinical information provided 
regarding the psoriatic group did not include such diagnosis. 
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Total 
cholesterol
HDL 
cholesterol
TC/HDL 
ratio
non-HDL 
cholesterol
LDL 
cholesterol
LDL/HDL 
ratio
Triglycerides ACE 
activity
Psoriatic 
patients
f 207.73±65.50
(n=11)
60.18±17.55
(n=11)
3.45±0.43
(n=11)
147.55±51.07
(n=11)
132.90±50.90
(n=10)
2.13±0.44
(n=10)
119.82±113.84
(n=11)
17.38±7.67
(n=6)
m 185.17±30.95
(n=24)
44.13±9.35
(n=23)
4.37±1.08
(n=23)
141.70±31.04
(n=23)
112.09±29.10
(n=22)
2.65±0.87
(n=22)
143.00±60.54
(n=25)
19.83±14.66
(n=14)
t 192.26±44.98
(n=35)
49.32±14.48
(n=34)
4.08±1.01
(n=34)
143.59±37.95
(n=34)
118.59±37.71
(n=32)
2.49±0.79
(n=32)
135.92±79.58
(n=36)
19.09±12.80
(n=20)
Controls f 200.54±36.89
(n=403)
63.87±14.42
(n=397)
3.27±0.83
(n=397)
137.07±35.39
(n=397)
118.13±33.26
(n=379)
1.95±0.72
(n=379)
96.20±43.07
(n=396)
11.61±6.75
(n=144)
m 195.77±42.56
(n=130)
51.63±12.79
(n=128)
3.96±1.09
(n=128)
144.17±40.96
(n=128)
122.04±37.08
(n=122)
2.48±0.89
(n=121)
129.20±86.06
(n=128)
13.41±7.97
(n=34)
t 199.37±38.37
(n=533)
60.89±14.98
(n=525)
3.44±0.95
(n=525)
138.80±36.91
(n=525)
119.09±34.23
(n=501)
2.08±0.80
(n=500)
104.26±58.32
(n=524)
11.95±7.01
(n=178)
p=0.143
p=0.473*
p<0.001 
p=0.011*
p<0.001
p=0.064*
p=0.479
p=0.758*
p=0.943
p=0.873*
p=0.007
p=0.233*
p=0.024
p=0.060*
p=0.023
p=0.003*
Table 6: means for the different parameters of the lipid profile with standard deviation and number of cases for each subgroup when excluded subjects with BMI≥30kg/m2; 
p-values calculated with t-test or Mann Whitney test according to the distribution of the samples; significance level defined at p≤0,050; 
*p-values adjusted for gender and age using linear regression; f-female, m-male, t-total
Image 1: on the left, HDL concentrations in psoriatic patients with mild (54.26±14.72) versus moderate to severe disease (41.67±11.04); 
on the right, triglyceride levels in patients with mild psoriasis (113.38±66.66) compared to patients with moderate to severe disease (163.56±44.95)
   
In order to estimate an association between psoriasis severity and cardiovascular risk, two 
subgroups of psoriatic patients were defined, knowing that PASI≤10 accounts for a mild psoriasis 
and  PASI>10  includes  both  moderate  to  severe  disease  [118].  The  results  in  table  7  show  a 
significant association with some of the features in the patient’s lipid profile. The HDL level is 
significantly lower in psoriatic patients with moderate to severe disease when comparing to mild 
psoriasis (image 1). TC/HDL ratio was found to be higher in patients with a more severe disease, as 
well as the triglycerides level that is shown to be significantly higher when PASI>10, all of which 
when adjusting for age and gender. A tendency was also found for an increase in LDL/HDL ratio 
with psoriatic severity, after the mentioned adjustment.
PASI was not found to be significantly correlated with the ACE genotype (one-way ANOVA 
test p=0.116) with a nonsignificant higher frequency of the II genotype in psoriatic patients with 
moderate to severe disease (OR=2.25, p=0.338).
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Total 
cholesterol
HDL 
cholesterol
TC/HDL 
ratio
non-HDL 
cholesterol
LDL 
cholesterol
LDL/HDL 
ratio
Triglycerides ACE activity
PASI
≤10
196.60±46.20
(n=20)
54.26±14.72
(n=19)
3.76±0.89
(n=19)
143.74±39.51
(n=19)
121.42±37.41
(n=19)
2.31±0.69
(n=19)
113.38±66.66
(n=21)
10.24±8.22
(n=5)
PASI
>10
196.44±38.42
(n=9)
41.67±11.04
(n=9)
4.88±1.02
(n=9)
154.78±32.57
(n=9)
121.13±36.60
(n=8)
3.01±0.89
(n=8)
163.56±44.95
(n=9)
17.20±11.03
(n=4)
p=0.814
p=0.604*
p=0.028
p=0.022*
p=0.012
p=0.011*
p=0.279
p=0.228*
p=0.811
p=0.559*
p=0.035
p=0.089*
p=0.021
p=0.020*
p=0.327
p=0.297*
Table 7: means for the different parameters of the lipid profile with standard deviation and number of cases for each subgroup; p-values calculated with t-test or Mann Whitney 
test according to the distribution of the samples; significance level defined at p≤0.05; *p-values adjusted for gender and age
Image 2: graph showing association between TC/HDL ratio and psoriasis severity 
(estimated by PASI); pearson’s correlation; significance level defined at p≤0.05
r=0.612, p<0.001
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Considering the fact that once PASI is divided into two groups there is some information that 
is lost in the analysis, the continuous variable was used to check for correlations with the pearson or 
spearman test (depending on the distribution). This showed that PASI is inversely associated with 
HDL cholesterol  (r=-0.496,  p=0.007)  and  positively  correlated  with  LDL/HDL ratio  (r=0.437, 
p=0.023) and triglycerides levels (r=0.421, p=0.020), indicating a decrease in HDL cholesterol with 
a concomitant increase in LDL/HDL ratio as well as in triglycerides with psoriasis severity. 
As  can  be  seen  in  image  2,  PASI  is  also  strongly  correlated  to  TC/HDL ratio  (r=0.612, 
p<0.001), which leads to believe that psoriasis severity is in fact associated with an increase in 
cardiovascular disease as the TC/HDL ratio is one of the lipid indices with higher predictive value 
[114, 119, 120]. 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Conclusions
This  study  found  an  association  between  psoriasis  and  a  higher  ACE  activity  level, 
independent of its genotype. This increase in ACE activity suggest an oxidative stress state that is 
characteristic of cardiovascular disorders since it is one of the precipitating factors in atherogenesis. 
The genotype was strongly associated with ACE activity as also found in previous studies, although 
no  association  between  the  ACE  I/D  polymorphism  and  this  disease  or  its  severity  could  be 
demonstrated in our population. It is felt that a larger psoriatic sample with their ACE activities 
measured would be of importance to assess the true influence of this enzyme in the cardiovascular 
risk seen in these patients, specially since there appears to be a nonsignificant increase in ACE 
activity in the population with increased cholesterol levels.
Psoriatic severity was associated with a higher cardiovascular risk estimated by a lower HDL 
concentrations (r=-0.496, p=0.007) and higher triglyceride levels (r=0.421, p=0.020), as well as TC/
HDL and LDL/HDL ratios (r=0.612, p<0.001 and r=0.437, p=0.023, respectively) which have been 
shown to have a stronger predictive value for cardiovascular diseases. 
Further  studies  are  crucial  in  order  to  keep  enhancing  our  knowledge  on  the  overlap  of 
inflammation and psoriasis as a systemic autoimmune chronic disease. In a similar study, it would 
be important to have more information, with special relevance in using a larger psoriatic population 
sample  and  having  better  information  regarding  BMI  and  other  comorbidities  that  alter 
cardiovascular risk, as mentioned before, as well as medication that could affect our lipid profile 
levels and underestimate the difference between populations. It would also be of value to have a 
control group that better represents the normal population, which might not be found within the 
hospital/clinic environment.
It would also be interesting to assess lipid function and form in psoriatic patients as they may 
have  deeper  disturbances  in  this  metabolism  than  just  merely  a  quantitative  issue,  as  can  be 
perceived in the literature.
Psoriatic patients should be seen as a risk group for cardiovascular disorders and controlled 
accordingly. New and better markers for severity and for assessing this risk, as ACE might be, may 
be of worthy pursuit.  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Attachments
Attachment 1:
Image 3: electrophoresis gel for the ACE i/d polymorphism; the first column shows a DD fenotype with a 
fragment of 190bp and the second shows the heterozygous phenotype with the D fragment and the I 
fragment with 477bp; II genotype not displayed in this set; performed in the lab in May 2015
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